KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Name: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
Published: 2019
License: Public Domain

Merck Sharp & Dohme LLC · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

carcinoma

carcinoma, non-small-cell lung, programmed cell death receptor 1 (pd-1, pd1), programmed cell death receptor ligand 1 (pd-l1, pdl1), programmed cell death receptor ligand 2 (pd-l2, pdl2), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Related documents